Osteoporosis prophylaxis in patients receiving chronic glucocorticoid therapy

Annals of Saudi Medicine

Volumn 29, Issue 3, 2009, Pages 215-218

  Sadat Ali, Mir ^a   Alelq, Abdulmohsen H ^a   Alshafei, Badar A ^a   Al Turki, Haifa A ^a   AbuJubara, Mohammed A ^a  

^a IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; GLUCOCORTICOID; PREDNISOLONE; VITAMIN D; BONE DENSITY CONSERVATION AGENT; VITAMIN;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; AWARENESS; BONE DENSITY; CHEMOPROPHYLAXIS; CHILD; DRUG INTERMITTENT THERAPY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENTERITIS; FEMALE; GRAFT VERSUS HOST REACTION; HEALTH CARE SYSTEM; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LONG TERM CARE; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NEPHRITIS; OSTEOPENIA; PATIENT MONITORING; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SCHOOL CHILD; SECONDARY OSTEOPOROSIS; STEROID THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; VITAMIN SUPPLEMENTATION; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; FOLLOW UP; MIDDLE AGED; OSTEOPOROSIS; PHOTON ABSORPTIOMETRY; TREATMENT OUTCOME;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; ADULT; BONE DENSITY CONSERVATION AGENTS; CALCIUM; CHILD; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PREDNISOLONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VITAMIN D; VITAMINS; YOUNG ADULT;

EID: 69449086222     PISSN: 02564947     EISSN: 13199226     Source Type: Journal    
DOI: 10.5144/0256-4947.2009.215     Document Type: Article

References (26)

1. Nichols KJ. Evaluation of osteoporosis. J Am Osteopath Assoc. 2000;100:S4-7.
2. Chopra A. Osteoporosis: a new understanding of its impact and pathogenesis. J Am Osteopath Assoc. 2000;100:S1-4.
3. Iqbal MM. Osteoporosis: Epidemiology, diagnosis and treatment. South Med J. 2000;93:2-18.
4. Bubshait D, Sadat-Ali M. Economic implications of osteoporosis-related femoral fractures in Saudi Arabian society. Calcif Tissue Int. 2007;81:455-458
5. McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol. 2008;20:131-137.
6. Mazziotti G, Angeli A, Bilezikian JP, Canalis E, Giustina A. Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab. 2006;17:144-9.
7. van Staa TP, Leufkens HG, Cooper C. The epidemiology of cortico-steroid-induced osteoporosis: a meta analysis. Osteoporosis Int. 2002;13:777-787
8. van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int. 2006;79:129-137. (Pubitemid 44440440)
9. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporosis Int. 2007;8:1319-1328.
10. Shaker JL, Lukert BP. Osteoporosis associated with excess glucocorticoids. Endocrinol Metab. Clin North Am. 2005;34:341-356.
11. Walsh IJ, Wong CA, Pringle M, Tattersfield AE. Use of oral corticosteroids in community and the prevention of secondary osteoporosis: a cross-sectional study. BMJ. 1996;313:344-346. (Pubitemid 26334822)
12. Gudbjornsson B, Juliusson UI, Gudjonsson FV. Prevalence of long-term steroid treatment and the frequency of decision making to prevent steroid-induced osteoporosis in daily clinical practice. Ann Rheum Dis. 2002;61:32-36. (Pubitemid 34074836)
13. Sadat-Ali M, Al-Elq A. Sickle cell disease: is it a cause for secondary osteoporosis? West African J Med. 2007;26(2):134-137.
14. Al-Amri A, Sadat-Ali M. Cancer chemotherapy induced osteoporosis: how common is it among Saudi Arabian cancer survivors. Ind J Cancer. Forthcoming 2009.
15. Morgan GA, Griego OV, Gloeckner GW. Statistical Package for the Social Sciences for Windows: An Introduction To Use and interpretation in Research [CD-ROM], version 14.0. SPSS Inc. Chicago, Illinois, 2007.
16. Painter SE, Kleerekoper M, Camacho PM. Secondary osteoporosis: a review of the recent evidence. Endocr Pract. 2006;12:436-445 (Pubitemid 44717606)
17. Steinbuch M, Youket TE, Cohen S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporosis Int. 2004;15:323-328 (Pubitemid 38543952)
18. Berris KK, Repp AL, Kleerekoper M. Glucocorticoid-induced osteoporosis. Curr Opin Endocrinol Diabetes Obes. 2007;14:446-450.
19. American College of Rheumatology Ad Hoc Committee on Glucocorticod- Induced Osteoporosis. Recommendation for the prevention and treatment of glucocorticod-induced osteoporosis. 2001 Update. Arthritis and Rheum. 2001;44:1496-1503.
20. Adler RA, Hochberg MC. Suggested guidelines for evaluation and treatment of glucocorticod-induced osteoporosis for the Department of Veterans Affairs. Arch Intern Med. 2003;163:2619-2624.
21. National Osteoporosis Society. Guidelines on the prevention and management of corticosteroid-induced osteoporosis, London NOS 1998.
22. Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, et al. A UK consensus group on management of glucocorticoid-induced osteoporosis. An update. J Intern Med. 1998;244:271-292 (Pubitemid 28473991)
23. Sadat-Ali M, Al Elq A. Osteoporosis among male Saudi Arabs. A pilot study. Ann Saudi Med. 2006;26:450-454.
24. Guzman-Clark JR, Fang MA, Sehl ME, Traylor L, Hahn TJ. Barrier in the management of glucocorticoid-induced osteoporosis. Arthritis Rheum. 2007;57:140-146.
25. Hart SR, Green B. Osteoporosis prophylaxis during corticosteroid treatment: failure to prescribe. Postgrad Med J. 2002;78:242-243 (Pubitemid 34293327)
26. Ungprasert S, Wangkaew S, Louthrenoo W. Physicians awareness of the prevention of corticosteroid induced osteoporosis. J Med Assoc Thai. 2007;90:59-64. (Pubitemid 46255394)